The immunoglobulin of yolk and cerium oxide-based fibrous poly(L-lactide-co-glycolide)/gelatin dressings enable skin regeneration in an infectious wound model by Xinyuan Zhao, Changwen Weng, Hao Feng, Muhammad Shafiq, Xinyi Wang, Lei Liu, Lu Han, Mohamed EL-Newehy, Meera Moydeen Abdulhameed, Zhengchao Yuan, Xiumei Mo, Yanbiao Wang

“…The immunoglobulin of yolk (IgY) exhibits immunotherapeutic potential for the potential treatment of antimicrobial-resistant pathogens, while cerium oxide nanoparticles (CeO2 NPs) could scavenge superoxide dismutase (SOD) and inflammation. …”
Get full text

Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content by Baohua Luo, Qingling An, Jingyu Lei, Dengxu Tan, Xiaoqiu Liu, Hui Li, Yong Zhao, Jing Qin, Caiqin Zhang, Yongbin Zhang, Changhong Shi

“…Resveratrol has been shown to regulate both intestinal microbiota and the immune microenvironment; therefore, we speculated that resveratrol may enhance the immunotherapeutic effect of α-PD-1 on PC. We constructed a double-humanized mouse model with both a humanized immune system and PC to evaluate the efficacy of different doses of resveratrol combined with anti-PD-1 mAb therapy and analyze the characteristics of the tumor immune microenvironment after treatment. …”
Get full text

Comprehensive analysis of scRNA-seq and bulk RNA-seq reveals the non-cardiomyocytes heterogeneity and novel cell populations in dilated cardiomyopathy by Siyu He, Chunyu Li, Mingxin Lu, Fang Lin, Sangyu Hu, Junfang Zhang, Luying Peng, Li Li

“…Infiltration and alterations in non-cardiomyocytes of the human heart involve crucially in the occurrence of DCM and associated immunotherapeutic approaches. Methods We constructed a single-cell transcriptional atlas of DCM and normal patients. …”
Get full text

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives by Héverton Mendes Araújo, Gabriel Acácio de Moura, Yasmim Mendes Rocha, Cristian Vicson Pinheiro Gomes, Valentina Nascimento e Melo de Oliveira, Ronaldo Nascimento de Oliveira, Larissa Deadame de Figueiredo Nicolete, Emanuel Paula Magalhães, Ramon R.P.P.B. de Menezes, Roberto Nicolete

“…Our findings underscore the significance of the 1,2,4-oxadiazole compound class and highlight the potential of 1,2,4-oxadiazole derivative 2 as an antitumoral and immunotherapeutic agent.…”
Get full text

Effect of chemoradiotherapy on the dynamics of circulating lymphocyte subsets in patients with non-metastatic nasopharyngeal carcinoma by Lilan Yi, Lilan Yi, Yinfang Gu, Yinfang Gu, Longhua Guo, Longhua Guo, Xiaofang Zou, Xiaofang Zou, Guowu Wu, Guowu Wu

“…Assessing the variations in the distribution of circulating lymphocyte subsets among patients with different clinical treatment responses will be helpful in developing protocols for the concurrent utilization of immunotherapeutic drugs and CRT.…”
Get full text

Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site by Maria Paula Roberti, Pornpimol Charoentong, Yanhong Lyu, Marten Meyer, Stefan B. Eichmüller, Patrick Schmidt, Frank Momburg, Miray Cetin, Felix Hartmann, Nektarios A. Valous, Albrecht Stenzinger, Laura Michel, Peter Lichter, Andreas Schneeweiss, Verena Thewes, Carlo Fremd, Inka Zörnig, Dirk Jäger

“…The easy and safe accessibility of skin biopsies overcomes the major hurdles of current TCR screening approaches and present exciting opportunities for the development of innovative immunotherapeutic strategies.…”
Get full text

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors by Chiara Giordano, Simona Carlomagno, Simona Carlomagno, Michela Falco, Claudia Cantoni, Claudia Cantoni, Massimo Vitale, Ignazio Caruana, Johannes Dirks, Alberto Serio, Letizia Muccio, Giulia Bartalucci, Alessandra Bo, Franco Locatelli, Franco Locatelli, Cristina Bottino, Cristina Bottino, Simona Sivori, Simona Sivori, Mariella Della Chiesa, Mariella Della Chiesa

“…This new protocol for expanding functional adaptive NK cells is safe, cost-effective and easily implementable in a GMP context, suitable for innovative immunotherapeutic purposes.…”
Get full text

PKCα regulates the secretion of PDL1-carrying small extracellular vesicles in a p53-dependent manner by Ren Zhang, Weilin Liao, Xi Chen, Junyi Wang, Jiaqi Li, Geer Chen, Weiyu Wu, Xiaoxuan Wang, Yao Zhang, Ziyu Chen, Xiaoyu Zhu, Zicong Lin, Yizhun Zhu, Lijuan Ma, Haijie Yu

“…Our findings suggest that targeting PKCα to modulate PD-L1 dynamics in NSCLC may be a promising therapeutic strategy to enhance the efficacy of immunotherapeutic interventions.…”
Get full text

A Turbo‐Charging System‐Like Contrast Agent for MRI‐Guided STING Pathway‐Activated Cancer Immunotherapy by Bin Ren, Sihua Yan, Zongheng Li, Ya Huang, Haobin Cai, Jing Yang, Qingdeng Fan, Chunmei Chen, Fanchao Que, Guochao Wu, Lin Huang, Ruilong Zhou, Jiaoyang Zhu, Chenggong Yan, Gang Liu, Zheyu Shen, Shipeng Ning

“…Turbo S with a low dosage of SR717 (8.9 mg kg−1) achieved a higher tumor immunotherapeutic efficacy than free SR717 with a high dosage (30 mg kg−1). …”
Get full text

SEC61 translocon gamma subunit is correlated with glycolytic activity, epithelial mesenchymal transition and the immune suppressive phenotyp... by Zhou Changshuai, Cui Huanhuan, Yang Yuechao, Chen Lei, Feng Mingtao, Gao Yang, Li Deheng, Li Liangdong, Chen Xin, Li Xiaoqiu, Cao Yiqun

“…These findings underscore the potential of SEC61G as a therapeutic target and predictive marker for immunotherapeutic responses in LUAD patients.…”
Get full text

Deciphering hub genes and immune landscapes related to neutrophil extracellular traps in rheumatoid arthritis: insights from integrated bioinformatics analyses and experiments by Yang Li, Yang Li, Jian Liu, Jian Liu, Yue Sun, Yue Sun, Yuedi Hu, Yuedi Hu, Qiao Zhou, Qiao Zhou, Chengzhi Cong, Chengzhi Cong, Yiming Chen, Yiming Chen

“…CRYBG1, RMM2, MMP1, and SLC19A2 were identified and validated as potential NET-associated biomarkers, offering insights for diagnostic tools and immunotherapeutic strategies in RA.…”
Get full text

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma by Zhong Zheng, Jian-Biao Wang, Rui Sun, Nan Wang, Xiang-Qin Weng, Tian-Yuan Xu, Di Fu, Yan Feng, Peng-Peng Xu, Shu Cheng, Li Wang, Yan Zhao, Bin Qu, Chuan-Xin Huang, Wei-Li Zhao

“…Dual targeting PD-L1 and 4-1BB could be an alternative immunotherapeutic strategy in the chemo-free era of FL treatment.…”
Get full text

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics by Julia Velz, Lena K. Freudenmann, Gioele Medici, Marissa Dubbelaar, Malte Mohme, David R. Ghasemi, Jonas Scheid, Daniel J. Kowalewski, Angelica B. Patterson, Anna M. Zeitlberger, Katrin Lamszus, Manfred Westphal, Matthias Eyrich, Martina Messing-Jünger, Andreas Röhrig, Harald Reinhard, Kévin Beccaria, Rogeiro B. Craveiro, Beat M. Frey, Martin Sill, Sven Nahnsen, Marie Gauder, Konstantina Kapolou, Manuela Silginer, Tobias Weiss, Hans-Georg Wirsching, Patrick Roth, Michael Grotzer, Niklaus Krayenbühl, Oliver Bozinov, Luca Regli, Hans-Georg Rammensee, Elisabeth J. Rushing, Felix Sahm, Juliane S. Walz, Michael Weller, Marian C. Neidert

“…Integration of immunopeptidomics, transcriptomics, and epigenetic data leads to the identification of a large set of actionable targets that can be further used for the translation into the clinical setting by facilitating the informed design of immunotherapeutic approaches to children with medulloblastoma.…”
Get full text

Polymorphisms in immunosuppression-related genes are associated with AML by Mingying Li, Mingying Li, Jingjing Ye, Jingjing Ye, Mengyuan Chang, Mengyuan Chang, Lei Feng, Lei Feng, Tingting Liu, Tingting Liu, Di Zhang, Di Zhang, Yuyan Wu, Yuyan Wu, Yuechan Ma, Yuechan Ma, Guangqiang Meng, Guangqiang Meng, Chunyan Ji, Chunyan Ji, Tao Sun, Tao Sun

“…The immunosuppressive microenvironment significantly impacts AML development and chemoresistance. Despite new immunotherapeutic strategies entering standard clinical care for various tumors, progress in AML remains poor. …”
Get full text

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melan... by Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Restuan Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich

“…Conclusions Our findings unraveled the pivotal role of RECQL4 in immune modulation and its potential as both a predictive biomarker and therapeutic target for optimising immunotherapeutic strategies across various cancer types. …”
Get full text

γδ T Cell‐mediated Tumor Immunity is Tightly Regulated by STING and TGF‐β Signaling Pathways by Jing Luo, Shengli Wang, Quanli Yang, Qianqian Fu, Chuyun Zhu, Tao Li, Shuxian Yang, Yin Zhao, Rong Guo, Xiaosong Ben, Yuzhen Zheng, Sitao Li, Guang Yang, Hongru Zhang, Hui Xiao, Zhengfan Jiang, Nan Yan, Dieter Kabelitz, Guodong Sun, Zvi Granot, Ligong Lu, Fuping You, Jianlei Hao, Zhinan Yin

“…These findings present a novel mechanism involving STING‐mediated IFN‐γ production in γδ T cells and hold significant implications for the development of potent immunotherapeutic approaches against cancer.…”
Get full text

ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling by Aziguli Tulamaiti, Shu-Yu Xiao, Yan Yang, Musitaba Mutailifu, Xia-Qing Li, Shi-Qi Yin, Hong-Tai Ma, Hong-Fei Yao, Lin-Li Yao, Li-Peng Hu, Jun Li, Shu-Heng Jiang, Zhi-Gang Zhang, Yan-Miao Huo, Dong-Xue Li, Xue-Li Zhang

“…Mechanistic studies revealed that ENO1 upregulated PD-L1 to prevent CD8+ T cells infiltration through the hypoxia-inducible factor (HIF)-1α signaling pathway, leading to PDAC progression.In conclusion, our findings indicate that ENO1 might serve as a potential biomarker for PDAC and a novel onco-immunotherapeutic target via its role in altering the TIME.…”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…The findings establish a strong preclinical rationale for the clinical evaluation of EphA2‐targeted CAR‐NK therapy as a novel immunotherapeutic option for paediatric sarcomas. Future research directions: Combining EphA2‐CAR NK cells with immune checkpoint inhibitors or other immunomodulatory agents could further enhance therapeutic outcomes and durability. …”
Get full text

Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy by Manal Ali Buabeid, El-Shaimaa A. Arafa, Ghulam Murtaza

“…Although cancer immunotherapeutics show better outcomes as compared with conventional approaches of cancer treatment, the currently used cancer immunotherapeutics have limited application in delivering cancer antigens to immune cells. …”
Get full text

Moringa oleifera Flower Extract Suppresses the Activation of Inflammatory Mediators in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages via NF-κB Pathway by Woan Sean Tan, Palanisamy Arulselvan, Govindarajan Karthivashan, Sharida Fakurazi

Get full text